Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for November 24, 2020

11/24/2020

 
Regulatory Update
 
The FDA approved lonafarnib (Zokinvy, Eiger BioPharmaceuticals) on 11/20/2020, to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in patients one year of age and older.
 
The FDA approved lumasiran (Oxlumo, Alnylam Pharmaceuticals) on 11/23/2020, for the treatment of primary hyperoxaluria type 1 (PH1). The drug is well tolerated with the most common adverse effects being injection site reaction and abdominal pain. The EMA also approved lumasiran for the treatment of PH1.
 
The FDA accepted the NDA for Apellis’ pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and set a PDUFA date for 5/14/2021.
 
The FDA designated ViiV’s cabotegravir a breakthrough therapy for the prevention of HIV infection.
 
The FDA granted Sanofi’s rilzabrutinib a Fast Track designation for the treatment of immune thrombocytopenia.
 
The FDA accepted the BLA for ADC Therapeutics’ loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and set a PDUFA date for 5/21/2021.
 
Novartis has licensed the rights to develop and market remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS).
 
Amgen ended it collaboration with Cytokinetics for the development and commercialization of omecamtiv mecarbil.
 
Announced Research Updates
 
Eiger announced in the 24-week, 26 patient, Phase IIa, open-label, LIFT trial, 17 of 22 patients (77%) that completed 24 weeks of treatment with the combination of lonafarnib, ritonavir and pegylated interferon lambda achieved a > 2 log IU/mL decline in HDV RNA with a median decline of 3 log IU/mL in patients with a chronic infection of the hepatitis D virus. At Week 48 (24 weeks after completing treatment), 5/22 patients (23%) had HDV RNA below detection and 11 of 20 patients (55%) demonstrated improvement in Histology Activity Index (HAI).
 
UniQure announced that in the 26-week, 54 patient, Phase HOPE-B trial, treatment with etranacogene dezaparvovec resulted in an increase in FIX activity from < 2% to 37.2% and 72% patients reporting no bleeding events in patients with hemophilia B.
 
Elevar Therapeutics announced that in a 30 patient, Phase I/II trial, treatment with apatinib plus nivolumab resulted in an overall response rate of 13.3% in patients with locally advanced unresectable or metastatic solid tumors.
 
Published Research Updates
 
In a 16-week, 558 patient, Phase II/III trial, fasinumab 9 mg every four weeks and every eight weeks reduced the daily low back pain intensity numeric rating score compared to placebo in patients with moderate-to-severe, chronic low back pain. The 6 mg dose was no better than placebo.
 
In the 24-month, 292 patient, Phase III, trial, patients treated with odanacatib increased lumbar bone mineral density by 5.6% more than placebo in men with osteoporosis. 
 
In the 76 patient Phase Ib/II ENCORE 601 trial, treatment with entinostat and pembrolizumab lead to an objective response rate (ORR) of 9.2%, which did not meet the prespecified ORR endpoint for positivity, in patients with non-small cell lung cancer
 
In a 183 patient, Phase I, open-label, dose-ranging trial, treatment with loncastuximab tesirine resulted in an ORR of 45.6% in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.